CA3055602A1 - Bruton's tyrosine kinase inhibitors - Google Patents

Bruton's tyrosine kinase inhibitors Download PDF

Info

Publication number
CA3055602A1
CA3055602A1 CA3055602A CA3055602A CA3055602A1 CA 3055602 A1 CA3055602 A1 CA 3055602A1 CA 3055602 A CA3055602 A CA 3055602A CA 3055602 A CA3055602 A CA 3055602A CA 3055602 A1 CA3055602 A1 CA 3055602A1
Authority
CA
Canada
Prior art keywords
pyrazin
phenyl
imidazo
pyrrolidin
methoxyphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3055602A
Other languages
English (en)
French (fr)
Inventor
Xibin Liao
Jia Li
Zhijian Lu
Yubo Zhou
Anhui GAO
Original Assignee
Suzhou Baijibugong Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Baijibugong Pharmaceutical Technology Co Ltd filed Critical Suzhou Baijibugong Pharmaceutical Technology Co Ltd
Publication of CA3055602A1 publication Critical patent/CA3055602A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3055602A 2017-03-22 2018-03-21 Bruton's tyrosine kinase inhibitors Pending CA3055602A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762474686P 2017-03-22 2017-03-22
US62/474,686 2017-03-22
PCT/US2018/023455 WO2018175512A1 (en) 2017-03-22 2018-03-21 Bruton's tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
CA3055602A1 true CA3055602A1 (en) 2018-09-27

Family

ID=63585694

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3055602A Pending CA3055602A1 (en) 2017-03-22 2018-03-21 Bruton's tyrosine kinase inhibitors

Country Status (12)

Country Link
US (3) US11554118B2 (enExample)
EP (1) EP3601264A4 (enExample)
JP (1) JP7219902B2 (enExample)
KR (1) KR102627756B1 (enExample)
CN (1) CN110494433B (enExample)
AU (1) AU2018237123B2 (enExample)
CA (1) CA3055602A1 (enExample)
EA (1) EA201992147A1 (enExample)
IL (1) IL269152B2 (enExample)
MX (1) MX2019011116A (enExample)
WO (1) WO2018175512A1 (enExample)
ZA (1) ZA201906887B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554118B2 (en) * 2017-03-22 2023-01-17 Xibin Liao Bruton's tyrosine kinase inhibitors
CA3126940A1 (en) * 2019-01-18 2020-07-23 Xibin Liao Bruton's tyrosine kinase inhibitors
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP7475370B2 (ja) * 2019-05-10 2024-04-26 河南知微生物医薬有限公司 ブルトン型チロシンキナーゼ阻害剤としての置換されている１－アミノ－１ｈ－イミダゾール－５－カルボキサミド
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111471048B (zh) * 2020-04-30 2021-06-15 成都海博为药业有限公司 一种具有含氮桥环、螺环或并环结构的化合物及其用途
CN115073468B (zh) * 2021-03-15 2023-12-22 药雅科技(上海)有限公司 咪唑并吡嗪类btk抑制剂的制备及用途
WO2022228302A1 (en) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Heteroaromatic carboxamide compounds and its use

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003290333A1 (en) * 2002-12-24 2004-07-22 Biofocus Plc Compound libraries of imidazo(1,5-a)pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
WO2005021545A1 (en) 2003-09-03 2005-03-10 Galapagos Nv IMIDAZO[1,5-a]PYRIDINE OR IMIDAZO[1,5-a]PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS
WO2008022060A2 (en) * 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
EP2529621B1 (en) * 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP2139487B1 (en) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
US8658794B2 (en) 2010-02-08 2014-02-25 Merck Sharp & Dohme B.V. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof
JP2014509616A (ja) 2011-03-31 2014-04-21 エーエムベーエルエーエム テクノロジー トランスファー ゲーエムベーハー 治療用イミダゾ［１，２−ａ］ピリジン化合物
GB2513821A (en) * 2011-06-28 2014-11-12 Andrew Levine Speech-to-text conversion
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
WO2013010869A1 (en) * 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
FR2985185B1 (fr) * 2012-01-04 2013-12-27 Sanofi Sa Utilisation en therapeutique de derives d'imidazopyridine
EP2809673B1 (en) 2012-01-31 2016-11-02 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as bruton's tyrosine kinase inhibitors
US9481682B2 (en) * 2013-01-23 2016-11-01 Merck Sharp & Dohme Corp. Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
JP2016533385A (ja) * 2013-08-22 2016-10-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルキニルアルコール及び使用方法
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
WO2016106623A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106652A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
WO2016106626A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
MA41614A (fr) * 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
US20180305350A1 (en) * 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
US20190008859A1 (en) * 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
CN106478633A (zh) * 2015-08-27 2017-03-08 正大天晴药业集团股份有限公司 一类布鲁顿酪氨酸激酶抑制剂
US20170071962A1 (en) 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
US20170035881A1 (en) * 2015-10-19 2017-02-09 Acerta Pharma B.V. Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
WO2017077507A1 (en) * 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
EP3426637B1 (en) 2016-03-11 2022-02-09 Angel Pharmaceutical Co., Ltd. Compounds and methods for modulating bruton's tyrosine kinase
US10640512B2 (en) 2016-06-30 2020-05-05 Hangzhou Sanyintai Pharmaceutical Technology Co., Ltd. Imidazopyrazinamine phenyl derivative and use thereof
CN109851620B (zh) * 2016-08-17 2020-08-07 深圳市塔吉瑞生物医药有限公司 用于抑制酪氨酸激酶活性的稠合双环类化合物
US11554118B2 (en) * 2017-03-22 2023-01-17 Xibin Liao Bruton's tyrosine kinase inhibitors

Also Published As

Publication number Publication date
EP3601264A1 (en) 2020-02-05
BR112019019588A2 (pt) 2020-04-22
US20190275037A1 (en) 2019-09-12
ZA201906887B (en) 2022-03-30
US20210121458A1 (en) 2021-04-29
MX2019011116A (es) 2020-02-05
JP7219902B2 (ja) 2023-02-09
IL269152A (en) 2019-11-28
IL269152B2 (en) 2023-11-01
EA201992147A1 (ru) 2020-02-20
CN110494433B (zh) 2023-03-17
US20210107903A1 (en) 2021-04-15
US11974999B2 (en) 2024-05-07
CN110494433A (zh) 2019-11-22
WO2018175512A1 (en) 2018-09-27
KR102627756B1 (ko) 2024-01-23
US10933063B2 (en) 2021-03-02
EP3601264A4 (en) 2021-03-24
US11554118B2 (en) 2023-01-17
AU2018237123A1 (en) 2019-10-10
JP2020511547A (ja) 2020-04-16
AU2018237123B2 (en) 2022-08-04
KR20190133199A (ko) 2019-12-02
IL269152B1 (en) 2023-07-01

Similar Documents

Publication Publication Date Title
AU2018237123B2 (en) Bruton's tyrosine kinase inhibitors
AU2017208998B2 (en) Bruton's tyrosine kinase inhibitors
CA2953798C (en) Aminopyridazinone compounds as protein kinase inhibitors
EP3414234A1 (en) Bruton's tyrosine kinase inhibitors
CA2947338A1 (en) Multi-fluoro-substituted compound as bruton's tyrosine kinase (btk) inhibitor
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
EP3911326A1 (en) Bruton's tyrosine kinase inhibitors
CA3093706A1 (en) Jak inhibitors
CA3104927A1 (en) Tricyclic compounds
EP3028703B1 (en) Piperidine derivatives as wnt signaling inhibitor
US10793566B2 (en) Bruton's tyrosine kinase inhibitors
BR112019019588B1 (pt) Composto e composição farmacêutica
EA042551B1 (ru) Ингибиторы тирозинкиназы брутона
CA3008653C (en) Bruton's tyrosine kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230321

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240912

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250110

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - SMALL

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250211

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250211

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250513

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250513

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251014

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251014

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20260216

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260504

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260805